<SEC-DOCUMENT>0001213900-25-091383.txt : 20250925
<SEC-HEADER>0001213900-25-091383.hdr.sgml : 20250925
<ACCEPTANCE-DATETIME>20250925083001
ACCESSION NUMBER:		0001213900-25-091383
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250925
FILED AS OF DATE:		20250925
DATE AS OF CHANGE:		20250925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		251340275

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0258741-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September
2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:&nbsp; 001-38723</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 25, 2025, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing it will advance its second
asset, a fully human anti-IL-6 receptor (&ldquo;IL-6R&rdquo;) monoclonal antibody, TZLS-501. There has been heightened industry activity
in the IL-6 pathway space, underscored by Novartis&rsquo; (NYSE: NVS)
recent acquisition of Tourmaline Bio (Nasdaq: TRML) for approximately
$1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal
foralumab as its lead program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is
being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934,
or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall
be expressly set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 25, 2025</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ke</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">eren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXHIBIT&nbsp;INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ea025874101ex99-1_tiziana.htm">Tiziana Life Sciences LTD Press Release, dated September 25, 2025</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025874101ex99-1_tiziana.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED SEPTEMBER 25, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOSTON,
MA, September 25, 2025</B> &ndash; Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)
(&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), today announces it will advance its second asset, a fully human anti-IL-6 receptor
(&ldquo;IL-6R&rdquo;) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored
by Novartis&rsquo; (NYSE: NVS) recent acquisition of Tourmaline Bio (Nasdaq:
TRML) for approximately $1.4 billion. Tiziana will pursue non-dilutive
funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TZLS-501
is a fully human anti-IL-6 receptor (&ldquo;IL-6R&rdquo;) monoclonal antibody (mAb) targeting both the membrane-bound and soluble forms
of IL-6R. This dual mechanism of action not only blocks IL-6R signaling but also reduces circulating IL-6 cytokines, which are recognized
drivers of inflammation, lung damage, and chronic fibrosis. Tiziana sees potential to develop TZLS-501 as a monotherapy, or in combination
with its lead candidate, foralumab, as well as with other anti-inflammatory and anti-infective agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
recent acquisition by Novartis further validates the importance of IL-6 therapeutics. Tiziana believes this an opportune time for the
parallel advancement of TZLS-501. Accordingly, Tiziana will pursue development of TZLS-501, while not diverting resources or focus from
ongoing clinical trials with foralumab.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excessive
IL-6 signaling plays a central role in multiple diseases, including rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS),
idiopathic pulmonary fibrosis (IPF), systemic lupus erythematosus, and various cancers. By reducing both receptor-mediated signaling
and circulating cytokine burden, TZLS-501 may offer therapeutic advantages in managing these acute and chronic inflammatory conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ivor
Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented, &ldquo;Novartis&rsquo; recent acquisition of Tourmaline demonstrates
how IL-6 therapy is increasingly valued in treating systemic inflammation and related diseases. While intranasal foralumab remains our
lead program and primary focus, we are reviewing development opportunities for TZLS-501 as a complementary asset. Our fully human IL-6
mAb has always been an exciting asset. With recent market developments, we feel it is an opportune time to explore TZLS-501&rsquo;s development.
Its unique ability to address both membrane-bound and soluble IL-6 signaling, positions it as a potentially powerful therapy for acute
and chronic inflammatory conditions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
TZLS-501</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TZLS-501,
a fully human mAb, was licensed from Novimmune, SA, (Geneva, CH) in 2017. IL-6 is a cytokine that binds to its receptor subunit IL-6R&alpha;
on the cell membrane, and is a major determinant in priming of pathogenic T cells to produce an inflammatory response. The receptor IL-6R&alpha;
can be shed in soluble form, sIL6R&alpha;, which binds to circulating IL-6 cytokine in the blood. The downstream signaling from this
complex mediates pro-inflammatory effects underlying inflammatory diseases. TZLS-501 acts via a dual mechanism by inhibiting IL-6R signaling
and depleting circulating levels of IL-6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Foralumab</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foralumab,
a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed
intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label
intermediate sized Expanded Access (EA) Program (NCT06802328) with either
an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied
in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive
multiple sclerosis (NCT06292923).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foralumab
is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab
represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.<SUP>[1],[2]</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Tiziana Life Sciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies
to enable alternative routes of immunotherapy. Tiziana&rsquo;s innovative nasal approach has the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab,
which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical
response in patients in studies to date. Tiziana&rsquo;s technology for alternative routes of immunotherapy has been patented with several
applications pending and is expected to allow for broad pipeline applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further inquiries:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Spencer, Business Development, and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt;  width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>[1]</SUP></TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt;  width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>[2]</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2309221120</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V .P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V+Q+J.N:=
M9^9HNCIJ$F.<S;=O_ >I_ UXSK/C?QE>7#P7%Y)IY4X,,$?ED?4GFO7]/\=^
M']0O);+[<MM>1.8Y+>Y'ELK X(YX-7]6T#2]>@"WMM'*<?+*O##Z,*U@U'XD
M<M:$ZB_=R/FV8ZC=DFXO;J8GJ9)6;^9JNNGO&P9"RMZJ<&O4M;\!3:5(9(#Y
M]H3P^.5]C_C6*=#?^Y7=%1DKH^?JUJM.7+-.YR45WK%KS!JE]$1_<G8?UK?T
M"_\ 'FMZBECINMWQ/5Y'?*QKZL2*V=*\&W6KW8BC79$#^\E(X4?U->L:3H^G
M^'--\BV58HE&Z25R 6/JQK&JXQTZG?@_:UO>=U$ET>QN-.TV*WNK^>^N ,R7
M$V,L?8#H/:K]>7^,?B:$_P")7X=/F7,K",W6.%R<?)ZGWKTJTB:"SAB=B[I&
MJLQ.22!R:Y'%K5GKPJ1DVH]"MK6LV'A_29]4U.?R+.  R/M+8R<#@<GDU#X>
M\1Z7XITI=3T>Y^T6C,4W["I##J"" :\G^._B_4;2PN?#4>BR/97,"2/J'S;5
M._H,#'\(ZGO7#_#OXGZYX2\+#3-/\+R:C )WD\]0^,G&1PI'&*DT/J6FJZOG
M:P.#@X.:\^\+^*]2\>^#-;;4=-N-!E1'B64!LX*9W+D Y%</^S[%&VJZW/%K
MEQ=[(U4V[(RJP)XDY/7C'XT >]T5X/=_&3Q_!>SQ+X'PJ2,H#6\S' /<C@U
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M5^ -7L]733I=0\;ZD^L23R;M/-P-C$.V%*[>FT#O0!ZW'&D,:QQHJ(HPJJ,
M#V%.KFOB!>7=AX%U6YL;E[:Z2,".9.J$L!D?G7+W'BW4W\$SP3S-;:_I=_;6
M=[LX+9E4!Q_LNIS^)H ]'N;2VO(O*NK>*>/.=DJ!AGZ&I$1(T5$4*BC"JHP
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##__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
